These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 2475690)

  • 1. The effects of age on the pharmacodynamics and pharmacokinetics of two formulations of verapamil.
    Hosie J; Hosie G; Meredith PA
    J Cardiovasc Pharmacol; 1989; 13 Suppl 4():S60-2. PubMed ID: 2475690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Verapamil and 24-hour ambulatory blood pressure monitoring in essential hypertension.
    Zachariah PK; Sheps SG; Schirger A; Spiekerman RE; O'Brien PC; Simpson KK
    Am J Cardiol; 1986 Feb; 57(7):74D-79D. PubMed ID: 3953429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of verapamil and norverapamil in patients with hypertension: a comparison of oral conventional and sustained release formulations.
    Jørgensen NP; Walstad RA
    Pharmacol Toxicol; 1988 Aug; 63(2):105-7. PubMed ID: 3186615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative efficacy, safety and pharmacokinetics of verapamil SR vs verapamil IR in hypertensive patients.
    Fuenmayor NT; Faggin BM; Cubeddu LX
    Drugs; 1992; 44 Suppl 1():1-11. PubMed ID: 1283570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of sustained-release verapamil: automatic ambulatory blood pressure monitoring.
    Zachariah PK; Sheps SG; Schriger A
    J Clin Hypertens; 1986 Sep; 2(3 Suppl):133S-142S. PubMed ID: 3540223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of mild to moderate hypertension with verapamil slow-release in outpatients. Collaborative Group of the Spanish League for the Fight Against Hypertension.
    Gómez Pajuelo C; Pérez Naranjo J; Ruiz Martínez I
    J Cardiovasc Pharmacol; 1989; 13 Suppl 4():S50-2. PubMed ID: 2475687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and duration of action of sustained-release verapamil in essential hypertension.
    McCormack PM; Latham AN; Mee F; Atkins N; O'Brien ET; O'Malley K
    J Cardiovasc Pharmacol; 1989; 13 Suppl 4():S34-7. PubMed ID: 2475682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of enalapril and sustained-release verapamil in older patients with mild to moderate essential hypertension.
    Weir MR; Cassidy CA; Hall PS; Lancaster A; Schubert C; Urick A; Saunders E; Kong BW; Jenkins P; Lavin PT
    Clin Ther; 1990; 12(2):139-48. PubMed ID: 2354483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Plasma levels and noninvasive hemodynamic profile of slow release verapamil (240 mg). A multicenter study].
    Vulpis V; Seccia TM; Ricci S; Pirrelli A
    Riv Eur Sci Med Farmacol; 1993; 15(5-6):227-35. PubMed ID: 7761676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the efficacy and tolerability of lisinopril and sustained-release verapamil in older patients with hypertension.
    Weir MR; Lavin PT
    Clin Ther; 1991; 13(3):401-8. PubMed ID: 1659494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel delivery system for verapamil designed to achieve maximal blood pressure control during the early morning.
    Neutel JM; Alderman M; Anders RJ; Weber MA
    Am Heart J; 1996 Dec; 132(6):1202-6. PubMed ID: 8969572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Noninvasive blood pressure monitoring evaluation of verapamil slow-release 240-mg antihypertensive effectiveness.
    Novo S; Alaimo G; Abrignani MG; Longo B; Muratore G; Strano A
    J Cardiovasc Pharmacol; 1989; 13 Suppl 4():S38-41. PubMed ID: 2475683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antihypertensive efficacy of sustained-release verapamil.
    Zachariah PK; Sheps SG; Oshrain C; Schirger A; Stein WJ
    J Clin Hypertens; 1987 Dec; 3(4):536-46. PubMed ID: 3330987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once a day verapamil in essential hypertension.
    Müller FB; Ha HR; Hotz H; Schmidlin O; Follath F; Bühler FR
    Br J Clin Pharmacol; 1986; 21 Suppl 2(Suppl 2):143S-147S. PubMed ID: 3530298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Verapamil SR and propranolol LA: a comparison of efficacy and side effects in the treatment of mild to moderate hypertension.
    Bochsler JA; Simmons RL; Ward PJ; Chester PC; Latham AN
    J Hum Hypertens; 1988 Mar; 1(4):305-10. PubMed ID: 3065507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fixed combination trandolapril/verapamil sustained-release: a review of its use in essential hypertension.
    Muijsers RB; Curran MP; Perry CM
    Drugs; 2002; 62(17):2539-67. PubMed ID: 12421112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative efficacy, safety, and kinetics of immediate- and slow-release verapamil in hispanic patients with essential hypertension.
    Fuenmayor NT; Faggin BM; Cubeddu LX
    J Cardiovasc Pharmacol; 1989; 13 Suppl 4():S53-6. PubMed ID: 2475688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of sustained-release verapamil therapy on the blood pressure at rest and on the pressor response to isometric exertion in hypertensive patients.
    Cardillo C; Musumeci V; Savi L; Guardigli R; Mores N; Folli G
    Eur J Clin Pharmacol; 1988; 34(6):549-53. PubMed ID: 3169108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural and functional myocardial responses to chronic treatment with the Ca2+ blocker verapamil (Calan-SR) in hypertensive patients.
    Howley JW; Formolo JM; Penney DG
    J Cardiovasc Pharmacol; 1993 Oct; 22(4):637-43. PubMed ID: 7505368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of slow-release verapamil on blood pressure and cardiovascular system in essential hypertension.
    Meric M; Adalet K; Erzengin F; Korkut F; Okur O; Büyüköztürk K
    J Cardiovasc Pharmacol; 1989; 13 Suppl 4():S42-4. PubMed ID: 2475684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.